当前位置: 首页 >> 检索结果
401. Prognostic Role of Residual Thrombus Burden Following Thrombectomy: Insights From the TOTAL Trial.
作者: Mohammad Alkhalil.;Michał Kuzemczak.;Robin Zhao.;Charalampos Kavvouras.;Warren J Cantor.;Christopher B Overgaard.;Shahar Lavi.;Vinoda Sharma.;Saqib Chowdhary.;Goran Stanković.;Saško Kedev.;Ivo Bernat.;Ravinay Bhindi.;Tej Sheth.;Kari Niemela.;Sanjit S Jolly.;Vladimír Džavík.
来源: Circ Cardiovasc Interv. 2022年15卷5期e011336页
It is unclear whether more effective forms of thrombus removal than current aspiration catheters would lead to improved outcomes. We sought to evaluate the prognostic role of residual thrombus burden (rTB), after manual thrombectomy, in patients undergoing primary percutaneous coronary intervention with routine manual thrombectomy in the TOTAL trial (Thrombectomy Versus PCI Alone).
402. Understanding Baseline Physical Activity in Cardiac Rehabilitation Enrollees Using Mobile Health Technologies.
作者: Jessica R Golbus.;Kashvi Gupta.;Rachel Stevens.;V Swetha Jeganathan.;Evan Luff.;Thomas Boyden.;Bhramar Mukherjee.;Predrag Klasnja.;Sachin Kheterpal.;Sarah Kohnstamm.;Brahmajee K Nallamothu.
来源: Circ Cardiovasc Qual Outcomes. 2022年15卷7期e009182页
Baseline physical activity in patients when they initiate cardiac rehabilitation is poorly understood. We used mobile health technology to understand baseline physical activity of patients initiating cardiac rehabilitation within a clinical trial to potentially inform personalized care.
403. Pharmacogenomic Study of Statin-Associated Muscle Symptoms in the ODYSSEY OUTCOMES Trial.
作者: William A Murphy.;Nan Lin.;Amy Damask.;Gregory G Schwartz.;P Gabriel Steg.;Michael Szarek.;Poulabi Banerjee.;Sergio Fazio.;Garen Manvelian.;Robert Pordy.;Alan R Shuldiner.;Charles Paulding.
来源: Circ Genom Precis Med. 2022年15卷3期e003503页
Statin-associated muscle symptoms (SAMS) are the most frequently reported adverse events for statin therapies. Previous studies have reported an association between the p.Val174Ala missense variant in SLCO1B1 and SAMS in simvastatin-treated subjects; however, evidence for genetic predictors of SAMS in atorvastatin- or rosuvastatin-treated subjects is currently lacking.
404. Text Messages to Improve Medication Adherence and Secondary Prevention After Acute Coronary Syndrome: The TEXTMEDS Randomized Clinical Trial.
作者: Clara K Chow.;Harry Klimis.;Aravinda Thiagalingam.;Julie Redfern.;Graham S Hillis.;David Brieger.;John Atherton.;Ravinay Bhindi.;Derek P Chew.;Nicholas Collins.;Michael Andrew Fitzpatrick.;Craig Juergens.;Nadarajah Kangaharan.;Andrew Maiorana.;Michele McGrady.;Rohan Poulter.;Pratap Shetty.;Jonathon Waites.;Christian Hamilton Craig.;Peter Thompson.;Sandrine Stepien.;Amy Von Huben.;Anthony Rodgers.; .
来源: Circulation. 2022年145卷19期1443-1455页
TEXTMEDS (Text Messages to Improve Medication Adherence and Secondary Prevention After Acute Coronary Syndrome) examined the effects of text message-delivered cardiac education and support on medication adherence after an acute coronary syndrome.
405. Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial.
作者: Remo H M Furtado.;Itamar Raz.;Erica L Goodrich.;Sabina A Murphy.;Deepak L Bhatt.;Lawrence A Leiter.;Darren K McGuire.;John P H Wilding.;Philip Aylward.;Anthony J Dalby.;Mikael Dellborg.;Doina Dimulescu.;José C Nicolau.;Anthonius J M Oude Ophuis.;Avivit Cahn.;Ofri Mosenzon.;Ingrid Gause-Nilsson.;Anna Maria Langkilde.;Marc S Sabatine.;Stephen D Wiviott.
来源: Circulation. 2022年145卷21期1581-1591页
Dapagliflozin improved heart failure and kidney outcomes in patients with type 2 diabetes (T2DM) with or at high risk for atherosclerotic cardiovascular disease in the DECLARE-TIMI 58 trial (Dapagliflozin Effect on Cardiovascular Events - Thrombolysis in Myocardial Infarction 58). Here, the aim was to analyze the efficacy and safety of dapagliflozin stratified according to baseline systolic blood pressure (SBP).
406. First-Line Catheter Ablation of Monomorphic Ventricular Tachycardia in Cardiomyopathy Concurrent With Defibrillator Implantation: The PAUSE-SCD Randomized Trial.
作者: Roderick Tung.;Yumei Xue.;Minglong Chen.;Chenyang Jiang.;Dalise Y Shatz.;Stephanie A Besser.;Hongde Hu.;Fa-Po Chung.;Shiro Nakahara.;Young-Hoon Kim.;Kazuhiro Satomi.;Lishui Shen.;Er'peng Liang.;Hongtao Liao.;Kai Gu.;Ruhong Jiang.;Jian Jiang.;Yuichi Hori.;Jong-Il Choi.;Akiko Ueda.;Yuki Komatsu.;Shuichiro Kazawa.;Kyoko Soejima.;Shih-Ann Chen.;Akihiko Nogami.;Yan Yao.; .
来源: Circulation. 2022年145卷25期1839-1849页
Catheter ablation as first-line therapy for ventricular tachycardia (VT) at the time of implantable cardioverter defibrillator (ICD) implantation has not been adopted into clinical guidelines. Also, there is an unmet clinical need to prospectively examine the role of VT ablation in patients with nonischemic cardiomyopathy, an increasingly prevalent population that is referred for advanced therapies globally.
407. Vitamin K2 and D in Patients With Aortic Valve Calcification: A Randomized Double-Blinded Clinical Trial.
作者: Axel C P Diederichsen.;Jes S Lindholt.;Sören Möller.;Kristian A Øvrehus.;Søren Auscher.;Jess Lambrechtsen.;Susanne E Hosbond.;Dilek H Alan.;Grazina Urbonaviciene.;Søren W Becker.;Maise H Fredgart.;Selma Hasific.;Lars Folkestad.;Oke Gerke.;Lars Melholt Rasmussen.;Jacob E Møller.;Hans Mickley.;Jordi S Dahl.
来源: Circulation. 2022年145卷18期1387-1397页
Menaquinone-7 (MK-7), also known as vitamin K2, is a cofactor for the carboxylation of proteins involved in the inhibition of arterial calcification and has been suggested to reduce the progression rate of aortic valve calcification (AVC) in patients with aortic stenosis.
408. Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF.
作者: Carly Adamson.;Kieran F Docherty.;Hiddo J L Heerspink.;Rudolf A de Boer.;Kevin Damman.;Silvio E Inzucchi.;Lars Køber.;Mikhail N Kosiborod.;Felipe A Martinez.;Mark C Petrie.;Piotr Ponikowski.;Marc S Sabatine.;Morten Schou.;Scott D Solomon.;Subodh Verma.;Olof Bengtsson.;Anna Maria Langkilde.;Mikaela Sjöstrand.;Muthiah Vaduganathan.;Pardeep S Jhund.;John J V McMurray.
来源: Circulation. 2022年146卷6期438-449页
In a post hoc analysis, the frequency of occurrence of an early decline (dip) in estimated glomerular filtration rate (eGFR) after initiation of dapagliflozin and its association with outcomes were evaluated in patients with heart failure and reduced ejection fraction randomized in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial.
409. Deep Lipidomics in Human Plasma: Cardiometabolic Disease Risk and Effect of Dietary Fat Modulation.
作者: Fabian Eichelmann.;Laury Sellem.;Clemens Wittenbecher.;Susanne Jäger.;Olga Kuxhaus.;Marcela Prada.;Rafael Cuadrat.;Kim G Jackson.;Julie A Lovegrove.;Matthias B Schulze.
来源: Circulation. 2022年146卷1期21-35页
In blood and tissues, dietary and endogenously generated fatty acids (FAs) occur in free form or as part of complex lipid molecules that collectively represent the lipidome of the respective tissue. We assessed associations of plasma lipids derived from high-resolution lipidomics with incident cardiometabolic diseases and subsequently tested if the identified risk-associated lipids were sensitive to dietary fat modification.
410. Relationship Between Social Vulnerability Indicators and Trial Participant Attrition: Findings From the HYVALUE Trial.
作者: Kamal H Henderson.;Laura J Helmkamp.;John F Steiner.;Edward P Havranek.;Suma X Vupputuri.;Rebecca Hanratty.;Irene V Blair.;Julie A Maertens.;Miriam Dickinson.;Stacie L Daugherty.
来源: Circ Cardiovasc Qual Outcomes. 2022年15卷5期e007709页
Social vulnerability indicators are associated with health care inequities and may similarly impede ongoing participation in research studies. We evaluated the association of social vulnerability indicators and research participant attrition in a trial focused on reducing health disparities.
411. Drug-Coated Balloon for Small Coronary Artery Disease in Patients With and Without High-Bleeding Risk in the BASKET-SMALL 2 Trial.
作者: Bruno Scheller.;Tuomas T Rissanen.;Ahmed Farah.;Marc-Alexander Ohlow.;Norman Mangner.;Jochen Wöhrle.;Sven Möbius-Winkler.;Daniel Weilenmann.;Gregor Leibundgut.;Florim Cuculi.;Nicole Gilgen.;Michael Coslovsky.;Felix Mahfoud.;Raban V Jeger.; .
来源: Circ Cardiovasc Interv. 2022年15卷4期e011569页
Patients at high-bleeding risk (HBR) undergoing percutaneous coronary intervention represent a challenging patient population. The use of drug-coated balloon (DCB) allows shorter duration of dual antiplatelet therapy compared with drug-eluting stents (DES) and reduces thrombotic risk due to the absence of a permanent implant. The present analysis aimed to investigate if the effect of DCB versus DES differed between patients with and without HBR treated with percutaneous coronary intervention in small coronary arteries.
412. Outcomes With Intermediate Left Main Disease: Analysis From the ISCHEMIA Trial.
作者: Sripal Bangalore.;John A Spertus.;Susanna R Stevens.;Philip G Jones.;G B John Mancini.;Jonathon Leipsic.;Harmony R Reynolds.;Matthew J Budoff.;Cameron J Hague.;James K Min.;William E Boden.;Sean M O'Brien.;Robert A Harrington.;Jeffrey S Berger.;Roxy Senior.;Jesus Peteiro.;Neeraj Pandit.;Leonid Bershtein.;Mark A de Belder.;Hanna Szwed.;Rolf Doerr.;Lorenzo Monti.;Khaled Alfakih.;Judith S Hochman.;David J Maron.; .
来源: Circ Cardiovasc Interv. 2022年15卷4期e010925页
Patients with significant (≥50%) left main disease (LMD) have a high risk of cardiovascular events, and guidelines recommend revascularization to improve survival. However, the impact of intermediate LMD (stenosis, 25%-49%) on outcomes is unclear.
413. Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial.
作者: Mikhail N Kosiborod.;Christiane E Angermann.;Sean P Collins.;John R Teerlink.;Piotr Ponikowski.;Jan Biegus.;Josep Comin-Colet.;João Pedro Ferreira.;Robert J Mentz.;Michael E Nassif.;Mitchell A Psotka.;Jasper Tromp.;Martina Brueckmann.;Jonathan P Blatchford.;Afshin Salsali.;Adriaan A Voors.
来源: Circulation. 2022年146卷4期279-288页
Patients hospitalized for acute heart failure experience poor health status, including a high burden of symptoms and physical limitations, and poor quality of life. SGLT2 (sodium-glucose cotransporter 2) inhibitors improve health status in chronic heart failure, but their effect on these outcomes in acute heart failure is not well characterized. We investigated the effects of the SGLT2 inhibitor empagliflozin on symptoms, physical limitations, and quality of life, using the Kansas City Cardiomyopathy Questionnaire (KCCQ) in the EMPULSE trial (Empagliflozin in Patients Hospitalized With Acute Heart Failure Who Have Been Stabilized).
414. Randomized Trial of Chocolate Touch Compared With Lutonix Drug-Coated Balloon in Femoropopliteal Lesions (Chocolate Touch Study).
作者: Mehdi H Shishehbor.;Thomas Zeller.;Martin Werner.;Marianne Brodmann.;Helen Parise.;Andrew Holden.;Michael Lichtenberg.;Sahil A Parikh.;Vikram S Kashyap.;Cody Pietras.;Daniela Tirziu.;Shiva Ardakani.;Ulrich Beschorner.;Prakash Krishnan.;Khusrow A Niazi.;Andreas U Wali.;Alexandra J Lansky.
来源: Circulation. 2022年145卷22期1645-1654页
First-generation drug-coated balloons (DCBs) have significantly reduced the rate of restenosis compared with balloon angioplasty alone; however, high rates of bailout stenting and dissections persist. The Chocolate Touch DCB is a nitinol constrained balloon designed to reduce acute vessel trauma and inhibit neointima formation and restenosis.
415. Edoxaban Versus Dual Antiplatelet Therapy for Leaflet Thrombosis and Cerebral Thromboembolism After TAVR: The ADAPT-TAVR Randomized Clinical Trial.
作者: Duk-Woo Park.;Jung-Min Ahn.;Do-Yoon Kang.;Kyung Won Kim.;Hyun Jung Koo.;Dong Hyun Yang.;Seung Chai Jung.;Byungjun Kim.;Yiu Tung Anthony Wong.;Cheung Chi Simon Lam.;Wei-Hsian Yin.;Jeng Wei.;Yung-Tsai Lee.;Hsien-Li Kao.;Mao-Shin Lin.;Tsung-Yu Ko.;Won-Jang Kim.;Se Hun Kang.;Sung-Cheol Yun.;Seung-Ah Lee.;Euihong Ko.;Hanbit Park.;Dae-Hee Kim.;Joon-Won Kang.;Jae-Hong Lee.;Seung-Jung Park.; .
来源: Circulation. 2022年146卷6期466-479页
It is unknown whether the direct oral anticoagulant edoxaban can reduce leaflet thrombosis and the accompanying cerebral thromboembolic risk after transcatheter aortic valve replacement. In addition, the causal relationship of subclinical leaflet thrombosis with cerebral thromboembolism and neurological or neurocognitive dysfunction remains unclear.
416. Presenting Symptoms in Patients Undergoing Coronary Artery Disease Evaluation: Association With Noninvasive Test Results and Clinical Outcomes in the PROMISE Trial.
作者: Angela Lowenstern.;Karen P Alexander.;Neha J Pagidipati.;C Larry Hill.;Patricia A Pellikka.;Lawton S Cooper.;Brooke Alhanti.;Udo Hoffmann.;Daniel B Mark.;Pamela S Douglas.
来源: Circ Cardiovasc Qual Outcomes. 2022年15卷5期e008298页
Patients evaluated for coronary artery disease have a range of symptoms and underlying risk. The relationships between patient-described symptoms, clinician conclusions, and subsequent clinical management and outcomes remain incompletely described.
417. Impact of Ticagrelor Versus Clopidogrel on Coronary Microvascular Function After Non-ST-Segment-Elevation Acute Coronary Syndrome.
作者: James Xu.;Sidney Lo.;Christian J Mussap.;John K French.;Rohan Rajaratnam.;Krishna Kadappu.;Upul Premawardhana.;Phong Nguyen.;Craig P Juergens.;Dominic Y Leung.
来源: Circ Cardiovasc Interv. 2022年15卷4期e011419页
Coronary microvascular dysfunction after acute coronary syndrome is an important predictor of long-term prognosis. Data is lacking on the effects of oral P2Y12-inhibitors on coronary microvascular function in non-ST-segment-elevation acute coronary syndrome. The aim of this study was to compare the acute effects of ticagrelor versus clopidogrel pretreatment on coronary microvascular function in non-ST-segment-elevation acute coronary syndrome patients.
418. Effect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70.
作者: Brian A Bergmark.;Nicholas A Marston.;Candace R Bramson.;Madelyn Curto.;Vesper Ramos.;Alexandra Jevne.;Julia F Kuder.;Jeong-Gun Park.;Sabina A Murphy.;Subodh Verma.;Wojtek Wojakowski.;Steven G Terra.;Marc S Sabatine.;Stephen D Wiviott.; .
来源: Circulation. 2022年145卷18期1377-1386页
Genetic loss-of-function variants in ANGPTL3 are associated with lower levels of plasma lipids. Vupanorsen is a hepatically targeted antisense oligonucleotide that inhibits Angiopoietin-like 3 (ANGPTL3) protein synthesis.
419. Quality of Life After Fractional Flow Reserve-Guided PCI Compared With Coronary Bypass Surgery.
作者: William F Fearon.;Frederik M Zimmermann.;Victoria Y Ding.;Jo M Zelis.;Zsolt Piroth.;Giedrius Davidavicius.;Samer Mansour.;Rajesh Kharbanda.;Nikolaos Östlund-Papadogeorgos.;Keith G Oldroyd.;Olaf Wendler.;Michael J Reardon.;Y Joseph Woo.;Alan C Yeung.;Nico H J Pijls.;Bernard De Bruyne.;Manisha Desai.;Mark A Hlatky.; .
来源: Circulation. 2022年145卷22期1655-1662页
Previous studies have shown that quality of life improves after coronary revascularization more so after coronary artery bypass grafting (CABG) than after percutaneous coronary intervention (PCI). This study aimed to evaluate the effect of fractional flow reserve guidance and current generation, zotarolimus drug-eluting stents on quality of life after PCI compared with CABG.
420. Does Timing of Ventricular Tachycardia Ablation Affect Prognosis in Patients With an Implantable Cardioverter Defibrillator? Results From the Multicenter Randomized PARTITA Trial.
作者: Paolo Della Bella.;Francesca Baratto.;Pasquale Vergara.;Patrizia Bertocchi.;Matteo Santamaria.;Pasquale Notarstefano.;Leonardo Calò.;Daniela Orsida.;Luca Tomasi.;Marcello Piacenti.;Stefano Sangiorgio.;Francesco Pentimalli.;Etienne Pruvot.;João De Sousa.;Frederic Sacher.;Massimo Tritto.;Luca Rebellato.;Thomas Deneke.;Salvo Andrea Romano.;Martina Nesti.;Alessio Gargaro.;Daniele Giacopelli.;Giovanni Peretto.;Andrea Radinovic.
来源: Circulation. 2022年145卷25期1829-1838页
Optimal timing for catheter ablation of ventricular tachycardia is an important unresolved issue. There are no randomized trials evaluating the benefit of ablation after the first implantable cardioverter defibrillator (ICD) shock.
|